Intravitreal injection of exendin-4 analogue protects retinal cells in early diabetic rats.

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Investigative Ophthalmology and Visual Science

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1167/iovs.09-4727PMID 20688733
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Protection of exendin-4 analogue in early experimental diabetic retinopathy

  2008cited by this paper
• Erythropoietin protects retinal neurons and glial cells in early-stage streptozotocin-induced diabetic rats.

  2008cited by this paper
• Glucagon-like peptide 1 receptor stimulation reverses key deficits in distinct rodent models of Parkinson's disease

  2008cited by this paper
• Projection of diabetic retinopathy and other major eye diseases among people with diabetes mellitus: United States, 2005-2050.

  2008influential reference
• Exenatide: its position in the treatment of type 2 diabetes.

  2008cited by this paper
• Effects of exendin‐4 on islets from type 2 diabetes patients

  2008cited by this paper
• Intravitreal injection of erythropoietin protects both retinal vascular and neuronal cells in early diabetes.

  2008cited by this paper
• Glucagon-like peptide 1 receptor expression in primary porcine proximal tubular cells.

  2007cited by this paper
• Glutaredoxin Regulates Nuclear Factor κ-B and Intercellular Adhesion Molecule in Müller Cells

  2007cited by this paper
• Downregulation of GLP-1 and GIP Receptor Expression by Hyperglycemia

  2007cited by this paper
• Glucagon-like peptide-1 receptor and proglucagon expression in mouse skin.

  2006cited by this paper
• Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury.

  2005cited by this paper
• Standard for clinical electroretinography (2004 update)

  2004cited by this paper
• Epithelial-to-Mesenchymal Transition Generates Proliferative Human Islet Precursor Cells

  2004cited by this paper
• Expression of apoptosis markers in the retinas of human subjects with diabetes.

  2004cited by this paper
• Oxidative stress affects synaptosomal gamma-aminobutyric acid and glutamate transport in diabetic rats: the role of insulin.

  2004cited by this paper
• Glucagon-like peptide-1 receptor is involved in learning and neuroprotection

  2003cited by this paper
• Effects of prolonged exendin-4 administration on entero-insular axis of normal and streptozotocin-induced diabetic rats.

  2003cited by this paper
• Prolonged exendin-4 administration stimulates pituitary-adrenocortical axis of normal and streptozotocin-induced diabetic rats.

  2003cited by this paper
• Degeneration of retinal neuronal processes and pigment epithelium in the early stage of the streptozotocin‐diabetic rats

  2002cited by this paper
• Therapy of type 2 diabetes mellitus based on the actions of glucagon‐like peptide‐1

  2002cited by this paper
• Diabetic retinopathy: more than meets the eye.

  2002cited by this paper
• A novel neurotrophic property of glucagon-like peptide 1: a promoter of nerve growth factor-mediated differentiation in PC12 cells.

  2002cited by this paper
• The glucagon-like peptides: a new genre in therapeutic targets for intervention in Alzheimer's disease

  2002cited by this paper
• Insulinotropic hormone glucagon-like peptide-1 differentiation of human pancreatic islet-derived progenitor cells into insulin-producing cells.

  2002cited by this paper
• Protection and Reversal of Excitotoxic Neuronal Damage by Glucagon-Like Peptide-1 and Exendin-4

  2002cited by this paper
• Glucagon-like peptide-1.

  2001cited by this paper
• Minireview: the glucagon-like peptides.

  2001cited by this paper
• Retinal neurodegeneration: early pathology in diabetes

  2000cited by this paper
• Simultaneous action of MK-801 (dizclopine) on dopamine, glutamate, aspartate and GABA release from striatum isolated nerve endings.

  2000cited by this paper
• Printed in U.S.A. Copyright © 2000 by The Endocrine Society Characterization of Human and Rat Glucagon-Like Peptide-1 Receptors in the Neurointermediate Lobe: Lack of Coupling to Either Stimulation or Inhibition of

  1999cited by this paper
• The glucagon-like peptides.

  1999cited by this paper
• Retinal TUNEL-positive cells and high glutamate levels in vitreous humor of mutant quail with a glaucoma-like disorder.

  1999cited by this paper
• The electroretinogram in diabetic retinopathy.

  1999cited by this paper
• Glucagon-like peptide-1 promotes DNA synthesis, activates phosphatidylinositol 3-kinase and increases transcription factor pancreatic and duodenal homeobox gene 1 (PDX-1) DNA binding activity in beta (INS-1)-cells

  1999cited by this paper
• Excitatory amino acid transporter 5, a retinal glutamate transporter coupled to a chloride conductance.

  1997cited by this paper
• High-affinity glutamate transporters in the rat retina: a major role of the glial glutamate transporter GLAST-1 in transmitter clearance

  1997cited by this paper
• Localisation of amino acid neurotransmitters during postnatal development of the rat retina

  1997cited by this paper
• Vitreous body glutamate concentration in dogs with glaucoma.

  1997cited by this paper
• Elevated glutamate levels in the vitreous body of humans and monkeys with glaucoma.

  1996cited by this paper
• An excitatory amino-acid transporter with properties of a ligand-gated chloride channel

  1995cited by this paper
• Distribution of GLP‐1 Binding Sites in the Rat Brain: Evidence that Exendin‐4 is a Ligand of Brain GLP‐1 Binding Sites

  1995cited by this paper
• Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in Type 2 (non-insulin-dependent) diabetic patients

  1993cited by this paper
• Nonvesicular release of neurotransmitter.

  1993cited by this paper
• Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting beta-cells.

  1993cited by this paper
• Cloning and expression of a rat brain L-glutamate transporter

  1992cited by this paper
• Structure, expression, and functional analysis of a Na(+)-dependent glutamate/aspartate transporter from rat brain.

  1992cited by this paper
• Primary structure and functional characterization of a high-affinity glutamate transporter

  1992cited by this paper
• Glutamate neurotoxicity and diseases of the nervous system.

  1988cited by this paper
• Oscillatory potential amplitudes. Relation to severity of diabetic retinopathy.

  1987cited by this paper
• L-glutamic acid: a neurotransmitter candidate for cone photoreceptors in human and rat retinas.

  1983cited by this paper
• Glial and neuronal uptake of GABA, glutamic acid, glutamine and glutathione in the rabbit retina.

  1977cited by this paper

• GLP-1 receptor agonists in eye disease: a comprehensive review of current research and future potential

  2026cites this paper
• GLP-1 receptor agonists as a strategy to target ER stress in diabetic retinopathy.

  2025cites this paper
• Autophagy-Induced Microglial Death Contributes to Neuroinflammation in Acute Optic Nerve Injury

  2025cites this paper
• New Insights Into Diabetes-Induced Cell-Type-Specific Responses in the Neural Retina via Single-Cell Transcriptomics: A Report on Research Supported by Pathway to Stop Diabetes.

  2025cites this paper
• Topical administration of GLP-1 eyedrops improves retinal ganglion cell function by facilitating presynaptic GABA release in early experimental diabetes

  2024cites this paper
• Induction of a Müller glial-specific protective pathway safeguards the retina from diabetes induced damage.

  2024cites this paper
• Exendin-4 promotes retinal ganglion cell survival and function by inhibiting calcium channels in experimental diabetes

  2023cites this paper
• Visual Dysfunction in Diabetes

  2023cites this paper
• The effect of GLP-1 receptor agonist lixisenatide on experimental diabetic retinopathy

  2023cites this paper
• Exendin-4, a GLP-1 receptor agonist, suppresses diabetic retinopathy in vivo and in vitro

  2023cites this paper
• RIP3-mediated microglial necroptosis promotes neuroinflammation and neurodegeneration in the early stages of diabetic retinopathy

  2023cites this paper
• Comprehensive review of glucagon-like peptide 1 receptor agonist treatment on the risk of cardiovascular outcomes and retinopathy as diabetic complications.

  2023cites this paper
• Anti-Inflammatory Effects of GLP-1R Activation in the Retina

  2022cites this paper
• Signaling Mechanism for Modulation by GLP-1 and Exendin-4 of GABA Receptors on Rat Retinal Ganglion Cells

  2022cites this paper
• Relevance of Peptide Homeostasis in Metabolic Retinal Degenerative Disorders: Curative Potential in Genetically Modified Mice

  2022cites this paper
• Targeted pharmacotherapy against neurodegeneration and neuroinflammation in early diabetic retinopathy.

  2021cites this paper
• Liraglutide Treatment Does Not Induce Changes in the Peripapillary Retinal Nerve Fiber Layer Thickness in Patients with Diabetic Retinopathy

  2021cites this paper
• Neurovascular Unit: A New Target for Treating Early Stages of Diabetic Retinopathy

  2021cites this paper
• Early (5-Day) Onset of Diabetes Mellitus Causes Degeneration of Photoreceptor Cells, Overexpression of Incretins, and Increased Cellular Bioenergetics in Rat Retina

  2021cites this paper
• Effects of the Topical Administration of Semaglutide on Retinal Neuroinflammation and Vascular Leakage in Experimental Diabetes

  2021influential citation
• Exendin-4 inhibits high glucose-induced oxidative stress in retinal pigment epithelial cells by modulating the expression and activation of p66Shc

  2021cites this paper
• Neurovascular unit in diabetic retinopathy: pathophysiological roles and potential therapeutical targets

  2021cites this paper
• Impact of Systemic Dipeptidyl Peptidase-4 Inhibitor Use in Diabetic Macular Edema.

  2020cites this paper
• Taurine Protects Retinal Cells and Improves Synaptic Connections in Early Diabetic Rats

  2020cites this paper
• Photoreceptor cells and RPE contribute to the development of diabetic retinopathy.

  2020cites this paper
• The effects of early diabetes on inner retinal neurons

  2020influential citation
• New anti-hyperglycaemic agents for type 2 diabetes and their effects on diabetic retinopathy

  2019cites this paper
• Microvascular and Cardiovascular Outcomes According to Renal Function in Patients Treated With Once-Weekly Exenatide: Insights From the EXSCEL Trial

  2019cites this paper
• Neuroprotective Peptides in Retinal Disease

  2019influential citation
• Topical ocular administration of the GLP-1 receptor agonist liraglutide arrests hyperphosphorylated tau-triggered diabetic retinal neurodegeneration via activation of GLP-1R/Akt/GSK3β signaling.

  2019cites this paper
• Relationships Between Neurodegeneration and Vascular Damage in Diabetic Retinopathy

  2019cites this paper
• GLP-1’s role in neuroprotection: a systematic review

  2019cites this paper
• Comparison of ELISA and HPLC-MS methods for the determination of exenatide in biological and biotechnology-based formulation matrices

  2019cites this paper
• Association Between Diabetic Microangiopathies and Glycemic Variability Assessed by Continuous Glucose Monitoring.

  2018cites this paper
• Astragaloside IV protects RGC-5 cells against oxidative stress

  2018cites this paper
• Tackling dipeptidyl peptidase IV in neurological disorders

  2018influential citation
• Glucagon-like peptide 1 receptor (GLP-1R) expression by nerve fibres in inflammatory bowel disease and functional effects in cultured neurons

  2018cites this paper
• Exendin‐4 attenuates neuronal death via GLP‐1R/PI3K/Akt pathway in early brain injury after subarachnoid hemorrhage in rats

  2018cites this paper
• diabetic retinopathy with rapid improvement in systemic glucose control: a

  2018cites this paper
• Worsening of diabetic retinopathy with rapid improvement in systemic glucose control: A review

  2018cites this paper
• Cardiovascular safety of GLP-1 receptor agonists for diabetes patients with high cardiovascular risk: A meta-analysis of cardiovascular outcomes trials.

  2018cites this paper
• The Urokinase Receptor-Derived Peptide UPARANT Recovers Dysfunctional Electroretinogram and Blood-Retinal Barrier Leakage in a Rat Model of Diabetes.

  2017cites this paper
• Topical administration of DPP-IV inhibitors prevents retinal neurodegeneration in experimental diabetes

  2017cites this paper
• Exploring the effects of DPP‐4 inhibitors on the kidney from the bench to clinical trials

  2017cites this paper
• Histologic Characterization of Retina Neuroglia Modifications in Diabetic Zucker Diabetic Fatty Rats.

  2017cites this paper
• Blocking IL-17A Alleviates Diabetic Retinopathy in Rodents

  2017cites this paper
• Diabetic retinopathy: research to clinical practice

  2017cites this paper
• GLP-1R as a Target for the Treatment of Diabetic Retinopathy: Friend or Foe?

  2017influential citation
• Retina Histologic Characterization of Retina Neuroglia Modifications in Diabetic Zucker Diabetic Fatty Rats

  2017cites this paper
• Diabetic retinopathy: new therapeutic perspectives based on pathogenic mechanisms

  2017cites this paper
• The potential benefits of glucagon-like peptide-1 receptor agonists for diabetic retinopathy.

  2017cites this paper
• Bariatric surgery is associated with less progression of diabetic retinopathy: A systematic review and meta-analysis.

  2017cites this paper
• Exendin-4 increases extracellular superoxide dismutase expression in cultured astrocytes

  2017cites this paper
• Retinal pigment epithelial cells express a functional receptor for glucagon-like peptide-1 ( GLP-1 ) PUDDU

  2017cites this paper
• The DPP4 Inhibitor Linagliptin Protects from Experimental Diabetic Retinopathy

  2016cites this paper
• IL-17A exacerbates diabetic retinopathy by impairing Müller cell function via Act1 signaling

  2016cites this paper
• Neuroprotection as a Therapeutic Target for Diabetic Retinopathy

  2016cites this paper
• The glucagon like peptide 1 analogue, exendin-4, attenuates oxidative stress-induced retinal cell death in early diabetic rats through promoting Sirt1 and Sirt3 expression.

  2016cites this paper
• Diabetes enhances the efficacy of AAV2 vectors in the retina: therapeutic effect of AAV2 encoding vasoinhibin and soluble VEGF receptor 1

  2016cites this paper
• Neurodegeneration as an early event in the pathogenesis of diabetic retinopathy: therapeutic implications /

  2016cites this paper
• Protective Effect of a GLP-1 Analog on Ischemia-Reperfusion Induced Blood–Retinal Barrier Breakdown and Inflammation

  2016cites this paper
• 2 . Neurodegeneration in DR and the Role of VEGF

  2016cites this paper
• Topical Administration of GLP-1 Receptor Agonists Prevents Retinal Neurodegeneration in Experimental Diabetes

  2015cites this paper
• Early retinal pigment epithelium dysfunction is concomitant with hyperglycemia in mouse models of type 1 and type 2 diabetes.

  2015cites this paper
• Hyperglycemia-induced GLP-1R downregulation causes RPE cell apoptosis.

  2015cites this paper
• Pigment Epithelium-Derived Factor Regulates Glutamine Synthetase and l-Glutamate/l-Aspartate Transporter in Retinas with Oxygen-induced Retinopathy

  2015cites this paper
• Incretin-Based Therapy for Prevention of Diabetic Vascular Complications

  2015cites this paper
• The effect of liraglutide on microvascular complications and cardiovascular risk in patients with type 2 diabetes

  2014cites this paper
• Exendin-4 alleviates retinal vascular leakage by protecting the blood-retinal barrier and reducing retinal vascular permeability in diabetic Goto-Kakizaki rats.

  2014cites this paper
• Neuropeptides, trophic factors, and other substances providing morphofunctional and metabolic protection in experimental models of diabetic retinopathy.

  2014cites this paper
• Dipeptidyl peptidase-IV inhibition prevents blood-retinal barrier breakdown, inflammation and neuronal cell death in the retina of type 1 diabetic rats.

  2014cites this paper
• Diabetes causes transient changes in the composition and phosphorylation of α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors and interaction with auxiliary proteins in the rat retina

  2014cites this paper
• Exendin-4 protects retinal cells from early diabetes in Goto-Kakizaki rats by increasing the Bcl-2/Bax and Bcl-xL/Bax ratios and reducing reactive gliosis

  2014influential citation
• The db/db Mouse: A Useful Model for the Study of Diabetic Retinal Neurodegeneration

  2014cites this paper
• Dipeptidyl Peptidase IV Inhibitor MK-0626 Attenuates Pancreatic Islet Injury in Tacrolimus-Induced Diabetic Rats

  2014cites this paper
• Treatment with hydrogen sulfide alleviates streptozotocin‐induced diabetic retinopathy in rats

  2013cites this paper
• Glucose‐dependent insulinotropic polypeptide and glucagon‐like peptide‐1: Incretin actions beyond the pancreas

  2013cites this paper
• Regression of diabetic macular edema after subcutaneous exenatide

  2013cites this paper
• Exendin-4 and GLP-1 decreases induced expression of ICAM-1, VCAM-1 and RAGE in human retinal pigment epithelial cells

  2013cites this paper
• Incretin actions beyond the pancreas: lessons from knockout mice.

  2013cites this paper
• Evaluation of a Dipeptidyl Peptidase IV Inhibitor as a Microvascular Protector in Diabetes

  2013influential citation
• Retinal Pigment Epithelial Cells Express a Functional Receptor for Glucagon-Like Peptide-1 (GLP-1)

  2013cites this paper
• Elevated glucose concentration changes the content and cellular localization of AMPA receptors in the retina but not in the hippocampus.

  2012cites this paper
• Exenatide prevents high-glucose-induced damage of retinal ganglion cells through a mitochondrial mechanism.

  2012cites this paper
• Neuroprotective and neurotrophic actions of glucagon‐like peptide‐1: an emerging opportunity to treat neurodegenerative and cerebrovascular disorders

  2012influential citation
• Bariatric Surgery Does Not Exacerbate and May Be Beneficial for the Microvascular Complications of Type 2 Diabetes

  2012cites this paper
• Protection of exenatide for retinal ganglion cells with different glucose concentrations.

  2012cites this paper
• Pleiotropic effects of glucagon-like peptide-1 (GLP-1)-based therapies on vascular complications in diabetes.

  2011cites this paper
• Glucose-Dependent Insulinotropic Polypeptide

  2011cites this paper
• World Journal of Diabetes

  year unknowncites this paper